NASDAQ:TERN

Terns Pharmaceuticals Stock Forecast, Price & News

$17.74

-1.19 (-6.29 %)

(As of 04/12/2021 04:46 PM ET)

Add

Compare

Today's Range

$17.00

Now: $17.74▼

$19.00

50-Day Range

$17.13

MA: $22.02▼

$27.25

52-Week Range

$14.83

Now: $17.74▼

$28.36

Volume75,438 shs

Average Volume205,242 shs

Market Capitalization$445.72 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TERN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.ternspharma.com

Phone650 525 5535

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares25,125,000

Market Cap$445.72 million

Next Earnings Date6/29/2021 (Estimated)

OptionableNot Optionable

Headlines

Terns Pharmaceuticals (NASDAQ:TERN) Shares Down 3.7%
April 7, 2021 | americanbankingnews.com

Terns to Present at the 19th Annual Virtual Needham HealthCare Conference
April 7, 2021 | finance.yahoo.com

Terns Pharmaceuticals (NASDAQ:TERN) Shares Down 6%
April 1, 2021 | americanbankingnews.com

Terns Pharmaceuticals (NASDAQ:TERN) Issues Earnings Results, Misses Estimates By $30.03 EPS
March 31, 2021 | americanbankingnews.com

Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 30, 2021 | finance.yahoo.com

Terns Announces Initiation of Dosing in Phase 1 Clinical Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH
March 22, 2021 | finance.yahoo.com

Terns Pharmaceuticals Inc Registered Shs Overweight
March 4, 2021 | markets.businessinsider.com

Dow Jones Rises Over 700 Points As Indexes Recover Some Of Last Week's Sell-Off; These Dow Stocks Trade Near Buy Zones
March 1, 2021 | finance.yahoo.com

Terns to Present at the Cowen 41st Annual Health Care Conference
February 23, 2021 | finance.yahoo.com

TERN.OQ - Terns Pharmaceuticals Inc Profile | Reuters
February 18, 2021 | reuters.com

Terns Pharmaceuticals Inc
February 16, 2021 | reuters.com

See More Headlines

MarketRank^™

Overall MarketRank^™

2.03 out of 5 stars

Medical Sector

51st out of 2,011 stocks

Biotechnology Industry

4th out of 143 stocks

3.5 Analyst's Opinion

Consensus Rating
Terns Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.50, Terns Pharmaceuticals has a forecasted upside of 72.7% from its current price of $17.66.
Amount of Analyst Coverage
Terns Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

5.0 Community Rank

Outperform Votes
Terns Pharmaceuticals has received 7 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Terns Pharmaceuticals has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Terns Pharmaceuticals has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Terns Pharmaceuticals and other stocks. Vote “Outperform” if you believe TERN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TERN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Terns Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Terns Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Terns Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,380,000.00 in company stock and sold $0.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$17.74

-1.19 (-6.29 %)

(As of 04/12/2021 04:46 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TERN News and Ratings via Email

Sign-up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter.

Terns Pharmaceuticals (NASDAQ:TERN) Frequently Asked Questions

Is Terns Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terns Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Terns Pharmaceuticals stock.
View analyst ratings for Terns Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Terns Pharmaceuticals?

Wall Street analysts have given Terns Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Terns Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Terns Pharmaceuticals' next earnings date?

Terns Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, June 29th 2021.
View our earnings forecast for Terns Pharmaceuticals.

How were Terns Pharmaceuticals' earnings last quarter?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) issued its earnings results on Monday, March, 29th. The company reported ($30.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by $30.03.
View Terns Pharmaceuticals' earnings history.

What price target have analysts set for TERN?

3 equities research analysts have issued 1 year price objectives for Terns Pharmaceuticals' stock. Their forecasts range from $29.00 to $32.00. On average, they expect Terns Pharmaceuticals' share price to reach $30.50 in the next year. This suggests a possible upside of 71.9% from the stock's current price.
View analysts' price targets for Terns Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Terns Pharmaceuticals' key executives?

Terns Pharmaceuticals' management team includes the following people:

Dr. Weidong Zhong Ph.D., Co-Founder, Chairman & Chief Scientific Officer (Age 55)
Mr. Senthil Vel Sundaram, CEO & Director (Age 43, Pay $358.33k)
Dr. Erin Quirk M.D., Pres & Chief Medical Officer (Age 50, Pay $495.07k)
Dr. Mark Joseph Vignola, Chief Financial Officer (Age 43, Pay $330k)
Mr. Seokho Yoon Esq., COO & Gen. Counsel (Age 43)

Who are some of Terns Pharmaceuticals' key competitors?

Some companies that are related to Terns Pharmaceuticals include ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), Cullinan Oncology (CGEM), Cricut (EWTX), Kinnate Biopharma (KNTE), Silverback Therapeutics (SBTX), Trillium Therapeutics (TRIL), Nurix Therapeutics (NRIX), Concordia International (CXR), Vor Biopharma (VOR), PureTech Health (PRTC), Connect Biopharma Holdings Limited American Depositary Shares (CNTB), iTeos Therapeutics (ITOS) and 4D Molecular Therapeutics (FDMT).
View all of TERN's competitors.

When did Terns Pharmaceuticals IPO?

(TERN) raised $101 million in an IPO on Friday, February 5th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO.

What is Terns Pharmaceuticals' stock symbol?

Terns Pharmaceuticals trades on the NASDAQ under the ticker symbol "TERN."

When does Terns Pharmaceuticals' lock-up period expire?

Terns Pharmaceuticals' lock-up period expires on Wednesday, August 4th. Terns Pharmaceuticals had issued 7,500,000 shares in its initial public offering on February 5th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. After the expiration of Terns Pharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Terns Pharmaceuticals?

Shares of TERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Terns Pharmaceuticals' stock price today?

One share of TERN stock can currently be purchased for approximately $17.74.

How much money does Terns Pharmaceuticals make?

Terns Pharmaceuticals has a market capitalization of $445.72 million.

What is Terns Pharmaceuticals' official website?

The official website for Terns Pharmaceuticals is www.ternspharma.com.

How can I contact Terns Pharmaceuticals?

The company can be reached via phone at 650 525 5535.

This page was last updated on 4/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Terns Pharmaceuticals Stock Forecast, Price & News

Adding

Adding

Adding Terns Pharmaceuticals, Inc.

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Headlines

MarketRank™

Overall MarketRank™

3.5 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage